Furthermore, another network meta-analysis demonstrated that SGLT-2 inhibitors, along with GLP-1RAs, had beneficial effects on mortality and major adverse cardiovascular events compared to DPP-4 inhibitors and glimepiride, particularly in high-risk populations, and were also the most effective in preventing hospitalization due to heart failure and kidney disease [107]. This evidence concerns the gene DPP4 and heart failure.